Bruce R. Conklin

Dr. Conklin’s research focuses on genome engineering to identify novel therapeutic approaches to human disease. By making precise genetic changes in induced pluripotent cells he seeks to reveal the cellular and molecular mechanisms of disease and identify new methods for therapeutic editing. He began his research career by working for two years at the National Institutes of Health with Nobel Laureate Julius Axelrod, Ph.D. He then completed his residency at Johns Hopkins Hospital and a postdoctoral fellowship in the laboratory of Henry Bourne, M.D., at the University of California, San Francisco (UCSF). In 1995, Dr. Conklin joined the Gladstone Institutes and the UCSF faculty where he is now a senior investigator at Gladstone and a professor at UCSF. Dr. Conklin is also the Gladstone Scientific Officer for Technology & Innovation and the deputy director of the Innovative Genomics Institute. He is the founder of BayGenomics, GenMAPP, AltAnalyze and WikiPathways. He pioneered the field of chemogenetics using designer GPCRs (RASSLs). He founded the Gladstone Genomics and Stem Cell Cores. He advises multiple organizations including the Allen Institute for Cell Science, the Chinese University of Hong Kong and the Exploratorium in San Francisco. He is a fellow in the California Academy of Sciences and a member the American Society for Clinical Investigation.